Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms

There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and the association with demographic, somatic and psychiatric factors remains unclear. Our aim was to explore whether levels of the novel LGI marker soluble urokina...

Full description

Saved in:
Bibliographic Details
Published inBMC psychiatry Vol. 21; no. 1; p. 527
Main Authors Bigseth, Therese Torgersen, Engh, John Abel, Egeland, Jens, Andersen, Eivind, Andreassen, Ole Andreas, Bang-Kittilsen, Gry, Falk, Ragnhild Sørum, Holmen, Tom Langerud, Lindberg, Morten, Mordal, Jon, Nielsen, Jimmi, Steen, Nils Eiel, Ueland, Thor, Vang, Torkel, Fredriksen, Mats
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 26.10.2021
BioMed Central
BMC
Subjects
Basale medisinske, odontologiske og veterinærmedisinske fag: 710
Basic medical, dental and veterinary science disciplines: 710
Biomarkers
Blood levels
Body mass index
C-reactive protein
C-Reactive Protein - analysis
Complications and side effects
CRP
Demographic aspects
Depression
Depression - complications
Depression, Mental
Development and progression
Female
Females
Gender differences
Genetic aspects
Health aspects
Humans
Immune response
Inflammation
Lipids
Male
Medical disciplines: 700
Medisinske Fag: 700
Mental depression
Mental disorders
Psychiatry
Receptors, Urokinase Plasminogen Activator
Risk factors
Schizophrenia
Schizophrenia - complications
Sex
suPAR
Tissue plasminogen activator
Tobacco smoking
U-Plasminogen activator
Urokinase
VDP
Norway
United States > US
CRP
Urokinase
Biomarker
Sex-difference
Immunesystem
suPAR
Schizophrenia
Depression
Inflammation
Online AccessGet full text

Cover

Abstract There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and the association with demographic, somatic and psychiatric factors remains unclear. Our aim was to explore whether levels of the novel LGI marker soluble urokinase plasminogen activator receptor (suPAR) were associated with clinical factors in schizophrenia and if such associations were sex-dependent. In this observational study a total of 187 participants with schizophrenia (108 males, 79 females) underwent physical examination and assessment with clinical interviews (Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Alcohol Use Disorder Identification Test (AUDIT), and Drug Use Disorder Identification Test (DUDIT)). Blood levels of suPAR, glucose, lipids, and high sensitivity C-reactive protein (hsCRP) were determined and body mass index (BMI) calculated. Multivariable linear regression analyses were used adjusting for confounders, and sex interaction tested in significant variables. Adjusting for sex, age, current tobacco smoking and BMI, we found that levels of hsCRP and depressive symptoms (CDSS) were positively associated with levels of suPAR (p < 0.001). The association between suPAR and CDSS score was significant in females (p < 0.001) but not in males. Immune activation measured by hsCRP was not associated with depressive symptoms after adjusting for BMI. Our findings indicate that increased suPAR levels are associated with depressive symptoms in females with schizophrenia, suggesting aberrant immune activation in this subgroup. Our results warrant further studies, including longitudinal follow-up of suPAR levels in schizophrenia and experimental studies of mechanisms.
AbstractList There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and the association with demographic, somatic and psychiatric factors remains unclear. Our aim was to explore whether levels of the novel LGI marker soluble urokinase plasminogen activator receptor (suPAR) were associated with clinical factors in schizophrenia and if such associations were sex-dependent. In this observational study a total of 187 participants with schizophrenia (108 males, 79 females) underwent physical examination and assessment with clinical interviews (Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Alcohol Use Disorder Identification Test (AUDIT), and Drug Use Disorder Identification Test (DUDIT)). Blood levels of suPAR, glucose, lipids, and high sensitivity C-reactive protein (hsCRP) were determined and body mass index (BMI) calculated. Multivariable linear regression analyses were used adjusting for confounders, and sex interaction tested in significant variables. Adjusting for sex, age, current tobacco smoking and BMI, we found that levels of hsCRP and depressive symptoms (CDSS) were positively associated with levels of suPAR (p < 0.001). The association between suPAR and CDSS score was significant in females (p < 0.001) but not in males. Immune activation measured by hsCRP was not associated with depressive symptoms after adjusting for BMI. Our findings indicate that increased suPAR levels are associated with depressive symptoms in females with schizophrenia, suggesting aberrant immune activation in this subgroup. Our results warrant further studies, including longitudinal follow-up of suPAR levels in schizophrenia and experimental studies of mechanisms.
Background - There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and the association with demographic, somatic and psychiatric factors remains unclear. Our aim was to explore whether levels of the novel LGI marker soluble urokinase plasminogen activator receptor (suPAR) were associated with clinical factors in schizophrenia and if such associations were sex-dependent. Method - In this observational study a total of 187 participants with schizophrenia (108 males, 79 females) underwent physical examination and assessment with clinical interviews (Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Alcohol Use Disorder Identification Test (AUDIT), and Drug Use Disorder Identification Test (DUDIT)). Blood levels of suPAR, glucose, lipids, and high sensitivity C-reactive protein (hsCRP) were determined and body mass index (BMI) calculated. Multivariable linear regression analyses were used adjusting for confounders, and sex interaction tested in significant variables. Results - Adjusting for sex, age, current tobacco smoking and BMI, we found that levels of hsCRP and depressive symptoms (CDSS) were positively associated with levels of suPAR (p < 0.001). The association between suPAR and CDSS score was significant in females (p < 0.001) but not in males. Immune activation measured by hsCRP was not associated with depressive symptoms after adjusting for BMI. Conclusion - Our findings indicate that increased suPAR levels are associated with depressive symptoms in females with schizophrenia, suggesting aberrant immune activation in this subgroup. Our results warrant further studies, including longitudinal follow-up of suPAR levels in schizophrenia and experimental studies of mechanisms.
Abstract Background There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and the association with demographic, somatic and psychiatric factors remains unclear. Our aim was to explore whether levels of the novel LGI marker soluble urokinase plasminogen activator receptor (suPAR) were associated with clinical factors in schizophrenia and if such associations were sex-dependent. Method In this observational study a total of 187 participants with schizophrenia (108 males, 79 females) underwent physical examination and assessment with clinical interviews (Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Alcohol Use Disorder Identification Test (AUDIT), and Drug Use Disorder Identification Test (DUDIT)). Blood levels of suPAR, glucose, lipids, and high sensitivity C-reactive protein (hsCRP) were determined and body mass index (BMI) calculated. Multivariable linear regression analyses were used adjusting for confounders, and sex interaction tested in significant variables. Results Adjusting for sex, age, current tobacco smoking and BMI, we found that levels of hsCRP and depressive symptoms (CDSS) were positively associated with levels of suPAR (p < 0.001). The association between suPAR and CDSS score was significant in females (p < 0.001) but not in males. Immune activation measured by hsCRP was not associated with depressive symptoms after adjusting for BMI. Conclusion Our findings indicate that increased suPAR levels are associated with depressive symptoms in females with schizophrenia, suggesting aberrant immune activation in this subgroup. Our results warrant further studies, including longitudinal follow-up of suPAR levels in schizophrenia and experimental studies of mechanisms.
Abstract Background There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and the association with demographic, somatic and psychiatric factors remains unclear. Our aim was to explore whether levels of the novel LGI marker soluble urokinase plasminogen activator receptor (suPAR) were associated with clinical factors in schizophrenia and if such associations were sex-dependent. Method In this observational study a total of 187 participants with schizophrenia (108 males, 79 females) underwent physical examination and assessment with clinical interviews (Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Alcohol Use Disorder Identification Test (AUDIT), and Drug Use Disorder Identification Test (DUDIT)). Blood levels of suPAR, glucose, lipids, and high sensitivity C-reactive protein (hsCRP) were determined and body mass index (BMI) calculated. Multivariable linear regression analyses were used adjusting for confounders, and sex interaction tested in significant variables. Results Adjusting for sex, age, current tobacco smoking and BMI, we found that levels of hsCRP and depressive symptoms (CDSS) were positively associated with levels of suPAR ( p  < 0.001). The association between suPAR and CDSS score was significant in females ( p  < 0.001) but not in males. Immune activation measured by hsCRP was not associated with depressive symptoms after adjusting for BMI. Conclusion Our findings indicate that increased suPAR levels are associated with depressive symptoms in females with schizophrenia, suggesting aberrant immune activation in this subgroup. Our results warrant further studies, including longitudinal follow-up of suPAR levels in schizophrenia and experimental studies of mechanisms.
There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and the association with demographic, somatic and psychiatric factors remains unclear. Our aim was to explore whether levels of the novel LGI marker soluble urokinase plasminogen activator receptor (suPAR) were associated with clinical factors in schizophrenia and if such associations were sex-dependent. In this observational study a total of 187 participants with schizophrenia (108 males, 79 females) underwent physical examination and assessment with clinical interviews (Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Alcohol Use Disorder Identification Test (AUDIT), and Drug Use Disorder Identification Test (DUDIT)). Blood levels of suPAR, glucose, lipids, and high sensitivity C-reactive protein (hsCRP) were determined and body mass index (BMI) calculated. Multivariable linear regression analyses were used adjusting for confounders, and sex interaction tested in significant variables. Adjusting for sex, age, current tobacco smoking and BMI, we found that levels of hsCRP and depressive symptoms (CDSS) were positively associated with levels of suPAR (p < 0.001). The association between suPAR and CDSS score was significant in females (p < 0.001) but not in males. Immune activation measured by hsCRP was not associated with depressive symptoms after adjusting for BMI. Our findings indicate that increased suPAR levels are associated with depressive symptoms in females with schizophrenia, suggesting aberrant immune activation in this subgroup. Our results warrant further studies, including longitudinal follow-up of suPAR levels in schizophrenia and experimental studies of mechanisms.
Background There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and the association with demographic, somatic and psychiatric factors remains unclear. Our aim was to explore whether levels of the novel LGI marker soluble urokinase plasminogen activator receptor (suPAR) were associated with clinical factors in schizophrenia and if such associations were sex-dependent. Method In this observational study a total of 187 participants with schizophrenia (108 males, 79 females) underwent physical examination and assessment with clinical interviews (Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Alcohol Use Disorder Identification Test (AUDIT), and Drug Use Disorder Identification Test (DUDIT)). Blood levels of suPAR, glucose, lipids, and high sensitivity C-reactive protein (hsCRP) were determined and body mass index (BMI) calculated. Multivariable linear regression analyses were used adjusting for confounders, and sex interaction tested in significant variables. Results Adjusting for sex, age, current tobacco smoking and BMI, we found that levels of hsCRP and depressive symptoms (CDSS) were positively associated with levels of suPAR (p < 0.001). The association between suPAR and CDSS score was significant in females (p < 0.001) but not in males. Immune activation measured by hsCRP was not associated with depressive symptoms after adjusting for BMI. Conclusion Our findings indicate that increased suPAR levels are associated with depressive symptoms in females with schizophrenia, suggesting aberrant immune activation in this subgroup. Our results warrant further studies, including longitudinal follow-up of suPAR levels in schizophrenia and experimental studies of mechanisms.
BACKGROUNDThere is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and the association with demographic, somatic and psychiatric factors remains unclear. Our aim was to explore whether levels of the novel LGI marker soluble urokinase plasminogen activator receptor (suPAR) were associated with clinical factors in schizophrenia and if such associations were sex-dependent. METHODIn this observational study a total of 187 participants with schizophrenia (108 males, 79 females) underwent physical examination and assessment with clinical interviews (Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Alcohol Use Disorder Identification Test (AUDIT), and Drug Use Disorder Identification Test (DUDIT)). Blood levels of suPAR, glucose, lipids, and high sensitivity C-reactive protein (hsCRP) were determined and body mass index (BMI) calculated. Multivariable linear regression analyses were used adjusting for confounders, and sex interaction tested in significant variables. RESULTSAdjusting for sex, age, current tobacco smoking and BMI, we found that levels of hsCRP and depressive symptoms (CDSS) were positively associated with levels of suPAR (p < 0.001). The association between suPAR and CDSS score was significant in females (p < 0.001) but not in males. Immune activation measured by hsCRP was not associated with depressive symptoms after adjusting for BMI. CONCLUSIONOur findings indicate that increased suPAR levels are associated with depressive symptoms in females with schizophrenia, suggesting aberrant immune activation in this subgroup. Our results warrant further studies, including longitudinal follow-up of suPAR levels in schizophrenia and experimental studies of mechanisms.
Background There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and the association with demographic, somatic and psychiatric factors remains unclear. Our aim was to explore whether levels of the novel LGI marker soluble urokinase plasminogen activator receptor (suPAR) were associated with clinical factors in schizophrenia and if such associations were sex-dependent. Method In this observational study a total of 187 participants with schizophrenia (108 males, 79 females) underwent physical examination and assessment with clinical interviews (Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Alcohol Use Disorder Identification Test (AUDIT), and Drug Use Disorder Identification Test (DUDIT)). Blood levels of suPAR, glucose, lipids, and high sensitivity C-reactive protein (hsCRP) were determined and body mass index (BMI) calculated. Multivariable linear regression analyses were used adjusting for confounders, and sex interaction tested in significant variables. Results Adjusting for sex, age, current tobacco smoking and BMI, we found that levels of hsCRP and depressive symptoms (CDSS) were positively associated with levels of suPAR (p < 0.001). The association between suPAR and CDSS score was significant in females (p < 0.001) but not in males. Immune activation measured by hsCRP was not associated with depressive symptoms after adjusting for BMI. Conclusion Our findings indicate that increased suPAR levels are associated with depressive symptoms in females with schizophrenia, suggesting aberrant immune activation in this subgroup. Our results warrant further studies, including longitudinal follow-up of suPAR levels in schizophrenia and experimental studies of mechanisms. Keywords: Schizophrenia, Depression, suPAR, Urokinase, CRP, Inflammation, Immunesystem, Biomarker, Sex-difference
ArticleNumber 527
Audience Academic
Author Bang-Kittilsen, Gry
Mordal, Jon
Vang, Torkel
Engh, John Abel
Bigseth, Therese Torgersen
Andersen, Eivind
Nielsen, Jimmi
Andreassen, Ole Andreas
Ueland, Thor
Egeland, Jens
Holmen, Tom Langerud
Steen, Nils Eiel
Fredriksen, Mats
Lindberg, Morten
Falk, Ragnhild Sørum
Author_xml – sequence: 1
  givenname: Therese Torgersen
  surname: Bigseth
  fullname: Bigseth, Therese Torgersen
  email: Therese.Torgersen@siv.no
  organization: Division of Mental Health and Addiction, Vestfold Hospital Trust, Sykehuset i Vestfold, PO Box 2168, 3103, Tonsberg, Norway. Therese.Torgersen@siv.no
– sequence: 2
  givenname: John Abel
  surname: Engh
  fullname: Engh, John Abel
  organization: Division of Mental Health and Addiction, Vestfold Hospital Trust, Sykehuset i Vestfold, PO Box 2168, 3103, Tonsberg, Norway
– sequence: 3
  givenname: Jens
  surname: Egeland
  fullname: Egeland, Jens
  organization: Department of Psychology, University of Oslo, PO Box 1094, Blindern, 0317, Oslo, Norway
– sequence: 4
  givenname: Eivind
  surname: Andersen
  fullname: Andersen, Eivind
  organization: Faculty of Humanities, Sports and Educational Science, University of South-Eastern Norway, PO Box 235, 3603, Kongsberg, Norway
– sequence: 5
  givenname: Ole Andreas
  surname: Andreassen
  fullname: Andreassen, Ole Andreas
  organization: NORMENT, Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, University of Oslo, Psychosis Research Unit/TOP, Ullevaal Hospital, building 49, PO Box 4956, Nydalen, 0424, Oslo, Norway
– sequence: 6
  givenname: Gry
  surname: Bang-Kittilsen
  fullname: Bang-Kittilsen, Gry
  organization: Division of Mental Health and Addiction, Vestfold Hospital Trust, Sykehuset i Vestfold, PO Box 2168, 3103, Tonsberg, Norway
– sequence: 7
  givenname: Ragnhild Sørum
  surname: Falk
  fullname: Falk, Ragnhild Sørum
  organization: Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, PO Box 4950, Nydalen, 0424, Oslo, Norway
– sequence: 8
  givenname: Tom Langerud
  surname: Holmen
  fullname: Holmen, Tom Langerud
  organization: Division of Mental Health and Addiction, Vestfold Hospital Trust, Sykehuset i Vestfold, PO Box 2168, 3103, Tonsberg, Norway
– sequence: 9
  givenname: Morten
  surname: Lindberg
  fullname: Lindberg, Morten
  organization: Department of Laboratory Medicine, Vestfold Hospital Trust, PO Box 2168, 3103, Tonsberg, Norway
– sequence: 10
  givenname: Jon
  surname: Mordal
  fullname: Mordal, Jon
  organization: Division of Mental Health and Addiction, Vestfold Hospital Trust, Sykehuset i Vestfold, PO Box 2168, 3103, Tonsberg, Norway
– sequence: 11
  givenname: Jimmi
  surname: Nielsen
  fullname: Nielsen, Jimmi
  organization: Mental Health Centre Glostrup, Copenhagen University Hospital, Copenhagen, Denmark
– sequence: 12
  givenname: Nils Eiel
  surname: Steen
  fullname: Steen, Nils Eiel
  organization: NORMENT, Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, University of Oslo, Psychosis Research Unit/TOP, Ullevaal Hospital, building 49, PO Box 4956, Nydalen, 0424, Oslo, Norway
– sequence: 13
  givenname: Thor
  surname: Ueland
  fullname: Ueland, Thor
  organization: K.G. Jebsen TREC, University of Tromso, 9037, Tromso, Norway
– sequence: 14
  givenname: Torkel
  surname: Vang
  fullname: Vang, Torkel
  organization: Mental Health Centre Glostrup, Copenhagen University Hospital, Copenhagen, Denmark
– sequence: 15
  givenname: Mats
  surname: Fredriksen
  fullname: Fredriksen, Mats
  organization: Division of Mental Health and Addiction, Vestfold Hospital Trust, Sykehuset i Vestfold, PO Box 2168, 3103, Tonsberg, Norway
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34702245$$D View this record in MEDLINE/PubMed
BookMark eNptks9u1DAQxiMEon_gBTiAJS5cUmzHTmwOSFVVoFIlLiBxs2adya6LYwc7u215HJ4Ub7etWoR88Mjzzc-e8XdQPQ0xYFW9YvSIMdW-z4wrpWrKWU0byXndPqn2mehYzYX48fRBvFcd5HxBKeuUZM-rvUZ0lHMh96s_p1eTj8mFJfHxkiwT9EhcGDyMI8wuBrK4Jjn69cIjWaf40wXISCYPeXQhLjEQsLPbwBwTSWhx2gYeN-hz4ZBsV-53nFYJg4MPBEjGq7rHCUOPYSaQc7Rud9Glm1ekpBLm7DZI8vVYYGN-UT0bwGd8ebsfVt8_nX47-VKff_18dnJ8XlupurkexKAVMKQDFX3TCwSpWEu51oiAFKwUGoXQrRBM8IUVHHqlYWCN0qqVQ3NYne24fYQLMyU3Qro2EZy5OYhpaSDNzno0XVdgzMphsJ1gUuq-42KhQFpoVd9AYX3csab1YsTell4T-EfQx5ngVmYZN0bJ8jUNL4A3O4BNLs8umBATGEZp0xnOtWqK4t3tFSn-WmOezeiyRe8hYFxnw6VqtW6olkX69h_pRVynUIZZVFpzySl9oFpCabF4IJaX2S3UHLdllKKRtC2qo_-oyupxdLYYdHDl_FEBv-sk5pxwuJ8Co2brY7PzsSk-Njc-Ntui1w_nd19yZ9zmL5hM8gU
CitedBy_id crossref_primary_10_3389_fpsyt_2023_1175171
crossref_primary_10_1007_s00406_023_01644_4
crossref_primary_10_3390_ijms232113054
Cites_doi 10.2174/1570159X16666180119144538
10.1111/acps.12783
10.1017/S0033291718004142
10.3389/fpsyt.2019.00892
10.1016/j.schres.2015.01.026
10.1038/s41380-018-0235-x
10.1186/s12979-018-0141-8
10.1038/s41386-018-0111-z
10.1093/schbul/sbw097
10.1373/clinchem.2004.033175
10.31857/S0026898420010097
10.1186/1741-7015-9-90
10.1038/s41598-018-35759-9
10.1371/journal.pone.0110555
10.1093/schbul/13.2.261
10.1016/S2215-0366(17)30293-6
10.1093/schbul/sbu118
10.17756/jnen.2018-039
10.1038/npp.2016.211
10.1016/j.biopsych.2018.06.016
10.1016/j.psychres.2019.07.005
10.1016/j.schres.2012.01.031
10.1016/j.atherosclerosis.2011.10.039
10.1016/j.psychres.2010.01.007
10.4137/BMI.S19876
10.1038/nri.2016.90
10.1038/mp.2016.3
10.1177/172460080101600402
10.1186/s13063-015-1094-2
10.1176/appi.ajp.2009.09030361
10.12740/PP/113222
10.1016/j.jacl.2010.02.005
10.1016/j.schres.2006.09.027
10.1038/s41598-018-21243-x
10.1016/j.psychres.2016.01.018
10.3389/fpsyt.2018.00753
10.1016/j.ijcard.2012.03.040
10.1001/jamapediatrics.2019.3875
10.1016/j.schres.2018.10.020
10.1111/eip.12946
10.1371/journal.pone.0140052
10.1016/j.schres.2020.11.051
10.1016/S0920-9964(02)00490-5
10.1177/1177271917704193
10.1371/journal.pone.0156624
10.1093/schbul/sbt200
10.1016/j.numecd.2019.05.066
10.1002/jmv.21114
10.1001/archpsyc.1992.01820080032005
10.1192/S0007125000292581
10.1038/tp.2015.88
10.1016/j.jad.2020.04.056
10.1016/j.psyneuen.2014.03.019
ContentType Journal Article
Copyright 2021. The Author(s).
COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
info:eu-repo/semantics/openAccess
The Author(s) 2021
Copyright_xml – notice: 2021. The Author(s).
– notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: info:eu-repo/semantics/openAccess
– notice: The Author(s) 2021
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7TK
7X7
7XB
88E
88G
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
K9.
M0S
M1P
M2M
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
7X8
3HK
5PM
DOA
DOI 10.1186/s12888-021-03522-6
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Neurosciences Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Psychology Database (Alumni)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
AUTh Library subscriptions: ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Psychology Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
MEDLINE - Academic
NORA - Norwegian Open Research Archives
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
ProQuest One Psychology
ProQuest Central Student
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Psychology Journals (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList


CrossRef
MEDLINE
Publicly Available Content Database
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-244X
EndPage 527
ExternalDocumentID oai_doaj_org_article_775491c5ffc741559d724b8a5ca68d3a
10037_22983
A681643506
10_1186_s12888_021_03522_6
34702245
Genre Research Support, Non-U.S. Gov't
Journal Article
Observational Study
GeographicLocations Norway
United States--US
GeographicLocations_xml – name: Norway
– name: United States--US
GroupedDBID ---
-A0
0R~
23N
2WC
3V.
53G
5VS
6J9
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
ABDBF
ABIVO
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
AZQEC
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
CGR
CS3
CUY
CVF
DIK
DWQXO
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
ECM
EIF
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
IPY
ITC
KQ8
M1P
M2M
M48
M~E
NPM
O5R
O5S
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
PSQYO
PSYQQ
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
AAYXX
CITATION
ABVAZ
AFGXO
AFNRJ
7TK
7XB
8FK
K9.
PQEST
PQUKI
PRINS
Q9U
7X8
123
2VQ
3HK
4.4
AAPBV
ABPTK
AHSBF
C1A
EJD
H13
IPNFZ
N95
RIG
5PM
ID FETCH-LOGICAL-c587t-f4f98a1e0f04d3d4ea58160299eeae0ac549e449644142bc42ad89af1389865f3
IEDL.DBID RPM
ISSN 1471-244X
IngestDate Tue Oct 22 14:53:50 EDT 2024
Tue Sep 17 21:27:09 EDT 2024
Sat Apr 29 05:43:19 EDT 2023
Thu Oct 24 23:39:10 EDT 2024
Thu Oct 10 19:35:03 EDT 2024
Thu Feb 22 23:50:56 EST 2024
Tue Nov 12 23:06:58 EST 2024
Thu Sep 12 17:49:19 EDT 2024
Sat Sep 28 08:30:40 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords CRP
Urokinase
Biomarker
Sex-difference
Immunesystem
suPAR
Schizophrenia
Depression
Inflammation
Language English
License 2021. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c587t-f4f98a1e0f04d3d4ea58160299eeae0ac549e449644142bc42ad89af1389865f3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
BMC Psychiatry
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547032/
PMID 34702245
PQID 2599252005
PQPubID 44775
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_775491c5ffc741559d724b8a5ca68d3a
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8547032
cristin_nora_10037_22983
proquest_miscellaneous_2586993095
proquest_journals_2599252005
gale_infotracmisc_A681643506
gale_infotracacademiconefile_A681643506
crossref_primary_10_1186_s12888_021_03522_6
pubmed_primary_34702245
PublicationCentury 2000
PublicationDate 2021-10-26
PublicationDateYYYYMMDD 2021-10-26
PublicationDate_xml – month: 10
  year: 2021
  text: 2021-10-26
  day: 26
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC psychiatry
PublicationTitleAlternate BMC Psychiatry
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References P Merino (3522_CR13) 2018; 4
PR Nielsen (3522_CR3) 2014; 40
J Ventura (3522_CR46) 2021; 15
A Onat (3522_CR40) 2010; 4
M Persson (3522_CR20) 2012; 220
GY Lim (3522_CR51) 2018; 8
S Niroumand (3522_CR41) 2015; 29
R Upthegrove (3522_CR49) 2017; 43
K Allsopp (3522_CR5) 2019; 279
R Nesvag (3522_CR38) 2010; 177
AS Brown (3522_CR2) 2010; 167
E Haastrup (3522_CR23) 2014; 9
JM Ramsey (3522_CR52) 2016; 11
RL Spitzer (3522_CR32) 1992; 49
AN Kaczkurkin (3522_CR29) 2019; 44
J Dahl (3522_CR9) 2014; 45
RS Wallwork (3522_CR35) 2012; 137
S Momtazmanesh (3522_CR44) 2019; 10
L Coin-Araguez (3522_CR17) 2018; 8
LJH Rasmussen (3522_CR42) 2019; 174
DR Goldsmith (3522_CR8) 2016; 21
SL Klein (3522_CR30) 2016; 16
L Orsolini (3522_CR11) 2018; 16
DW Hosmer (3522_CR43) 2012
RH Morch (3522_CR7) 2017; 136
M Brink (3522_CR55) 2019; 206
A Gustafsson (3522_CR22) 2017; 12
D Addington (3522_CR34) 1993; 22
O Andersen (3522_CR16) 2008; 80
AE Cullen (3522_CR4) 2019; 85
J Nielsen (3522_CR26) 2015; 41
BJ Miller (3522_CR1) 2017; 42
RA Kroken (3522_CR6) 2018; 9
A Wichniak (3522_CR37) 2019; 53
JA Engh (3522_CR31) 2015; 16
PS Klimovich (3522_CR14) 2020; 54
TH Haupt (3522_CR18) 2014; 9
TA Pollak (3522_CR53) 2018; 5
RR Conley (3522_CR47) 2007; 90
S Lyngbaek (3522_CR12) 2013; 167
RH Morch (3522_CR28) 2019; 49
S Sarro (3522_CR36) 2004; 68
TH Haupt (3522_CR19) 2019; 16
A Genc (3522_CR27) 2016; 236
TT Bigseth (3522_CR25) 2021; 228
HQ Cai (3522_CR10) 2020; 25
M Bot (3522_CR21) 2015; 5
M Dobiasova (3522_CR39) 2004; 50
W Li (3522_CR48) 2020; 273
C Noto (3522_CR45) 2015; 164
M Cabral (3522_CR54) 2019; 29
R Riisbro (3522_CR15) 2001; 16
E Bromet (3522_CR50) 2011; 9
SR Kay (3522_CR33) 1987; 13
F Ventorp (3522_CR24) 2015; 10
References_xml – volume: 16
  start-page: 583
  issue: 5
  year: 2018
  ident: 3522_CR11
  publication-title: Curr Neuropharmacol
  doi: 10.2174/1570159X16666180119144538
  contributor:
    fullname: L Orsolini
– volume: 136
  start-page: 400
  issue: 4
  year: 2017
  ident: 3522_CR7
  publication-title: Acta Psychiatr Scand
  doi: 10.1111/acps.12783
  contributor:
    fullname: RH Morch
– volume: 49
  start-page: 1749
  issue: 10
  year: 2019
  ident: 3522_CR28
  publication-title: Psychol Med
  doi: 10.1017/S0033291718004142
  contributor:
    fullname: RH Morch
– volume: 10
  start-page: 892
  year: 2019
  ident: 3522_CR44
  publication-title: Front Psychiatry
  doi: 10.3389/fpsyt.2019.00892
  contributor:
    fullname: S Momtazmanesh
– volume: 164
  start-page: 53
  issue: 1–3
  year: 2015
  ident: 3522_CR45
  publication-title: Schizophr Res
  doi: 10.1016/j.schres.2015.01.026
  contributor:
    fullname: C Noto
– volume: 25
  start-page: 761
  issue: 4
  year: 2020
  ident: 3522_CR10
  publication-title: Mol Psychiatry
  doi: 10.1038/s41380-018-0235-x
  contributor:
    fullname: HQ Cai
– volume: 16
  start-page: 1
  issue: 1
  year: 2019
  ident: 3522_CR19
  publication-title: Immun Ageing
  doi: 10.1186/s12979-018-0141-8
  contributor:
    fullname: TH Haupt
– volume: 44
  start-page: 71
  issue: 1
  year: 2019
  ident: 3522_CR29
  publication-title: Neuropsychopharmacology
  doi: 10.1038/s41386-018-0111-z
  contributor:
    fullname: AN Kaczkurkin
– volume: 43
  start-page: 240
  issue: 2
  year: 2017
  ident: 3522_CR49
  publication-title: Schizophr Bull
  doi: 10.1093/schbul/sbw097
  contributor:
    fullname: R Upthegrove
– volume: 50
  start-page: 1113
  issue: 7
  year: 2004
  ident: 3522_CR39
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2004.033175
  contributor:
    fullname: M Dobiasova
– volume: 54
  start-page: 103
  issue: 1
  year: 2020
  ident: 3522_CR14
  publication-title: Mol Biol (Mosk)
  doi: 10.31857/S0026898420010097
  contributor:
    fullname: PS Klimovich
– volume: 9
  start-page: 90
  issue: 1
  year: 2011
  ident: 3522_CR50
  publication-title: BMC Med
  doi: 10.1186/1741-7015-9-90
  contributor:
    fullname: E Bromet
– start-page: 90
  volume-title: Medical statistics : in clinical and epidemiological research
  year: 2012
  ident: 3522_CR43
  contributor:
    fullname: DW Hosmer
– volume: 8
  start-page: 17518
  issue: 1
  year: 2018
  ident: 3522_CR17
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-35759-9
  contributor:
    fullname: L Coin-Araguez
– volume: 9
  start-page: e110555
  issue: 10
  year: 2014
  ident: 3522_CR23
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0110555
  contributor:
    fullname: E Haastrup
– volume: 13
  start-page: 261
  issue: 2
  year: 1987
  ident: 3522_CR33
  publication-title: Schizophr Bull
  doi: 10.1093/schbul/13.2.261
  contributor:
    fullname: SR Kay
– volume: 5
  start-page: 79
  issue: 1
  year: 2018
  ident: 3522_CR53
  publication-title: Lancet Psychiatry
  doi: 10.1016/S2215-0366(17)30293-6
  contributor:
    fullname: TA Pollak
– volume: 41
  start-page: 764
  issue: 3
  year: 2015
  ident: 3522_CR26
  publication-title: Schizophr Bull
  doi: 10.1093/schbul/sbu118
  contributor:
    fullname: J Nielsen
– volume: 4
  start-page: 24
  issue: 2
  year: 2018
  ident: 3522_CR13
  publication-title: J Neurol Exp Neurosci
  doi: 10.17756/jnen.2018-039
  contributor:
    fullname: P Merino
– volume: 42
  start-page: 299
  issue: 1
  year: 2017
  ident: 3522_CR1
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2016.211
  contributor:
    fullname: BJ Miller
– volume: 85
  start-page: 35
  issue: 1
  year: 2019
  ident: 3522_CR4
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2018.06.016
  contributor:
    fullname: AE Cullen
– volume: 279
  start-page: 15
  year: 2019
  ident: 3522_CR5
  publication-title: Psychiatry Res
  doi: 10.1016/j.psychres.2019.07.005
  contributor:
    fullname: K Allsopp
– volume: 137
  start-page: 246
  issue: 1–3
  year: 2012
  ident: 3522_CR35
  publication-title: Schizophr Res
  doi: 10.1016/j.schres.2012.01.031
  contributor:
    fullname: RS Wallwork
– volume: 220
  start-page: 502
  issue: 2
  year: 2012
  ident: 3522_CR20
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2011.10.039
  contributor:
    fullname: M Persson
– volume: 177
  start-page: 228
  issue: 1–2
  year: 2010
  ident: 3522_CR38
  publication-title: Psychiatry Res
  doi: 10.1016/j.psychres.2010.01.007
  contributor:
    fullname: R Nesvag
– volume: 9
  start-page: 91
  year: 2014
  ident: 3522_CR18
  publication-title: Biomark Insights
  doi: 10.4137/BMI.S19876
  contributor:
    fullname: TH Haupt
– volume: 16
  start-page: 626
  issue: 10
  year: 2016
  ident: 3522_CR30
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri.2016.90
  contributor:
    fullname: SL Klein
– volume: 21
  start-page: 1696
  issue: 12
  year: 2016
  ident: 3522_CR8
  publication-title: Mol Psychiatry
  doi: 10.1038/mp.2016.3
  contributor:
    fullname: DR Goldsmith
– volume: 16
  start-page: 233
  issue: 4
  year: 2001
  ident: 3522_CR15
  publication-title: Int J Biol Markers
  doi: 10.1177/172460080101600402
  contributor:
    fullname: R Riisbro
– volume: 16
  start-page: 557
  issue: 1
  year: 2015
  ident: 3522_CR31
  publication-title: Trials
  doi: 10.1186/s13063-015-1094-2
  contributor:
    fullname: JA Engh
– volume: 167
  start-page: 261
  issue: 3
  year: 2010
  ident: 3522_CR2
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.2009.09030361
  contributor:
    fullname: AS Brown
– volume: 53
  start-page: 1191
  issue: 6
  year: 2019
  ident: 3522_CR37
  publication-title: Psychiatr Pol
  doi: 10.12740/PP/113222
  contributor:
    fullname: A Wichniak
– volume: 4
  start-page: 89
  issue: 2
  year: 2010
  ident: 3522_CR40
  publication-title: J Clin Lipidol
  doi: 10.1016/j.jacl.2010.02.005
  contributor:
    fullname: A Onat
– volume: 90
  start-page: 186
  issue: 1–3
  year: 2007
  ident: 3522_CR47
  publication-title: Schizophr Res
  doi: 10.1016/j.schres.2006.09.027
  contributor:
    fullname: RR Conley
– volume: 8
  start-page: 2861
  issue: 1
  year: 2018
  ident: 3522_CR51
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-21243-x
  contributor:
    fullname: GY Lim
– volume: 236
  start-page: 179
  year: 2016
  ident: 3522_CR27
  publication-title: Psychiatry Res
  doi: 10.1016/j.psychres.2016.01.018
  contributor:
    fullname: A Genc
– volume: 9
  start-page: 753
  year: 2018
  ident: 3522_CR6
  publication-title: Front Psychiatry
  doi: 10.3389/fpsyt.2018.00753
  contributor:
    fullname: RA Kroken
– volume: 167
  start-page: 781
  issue: 3
  year: 2013
  ident: 3522_CR12
  publication-title: Int J Cardiol
  doi: 10.1016/j.ijcard.2012.03.040
  contributor:
    fullname: S Lyngbaek
– volume: 174
  start-page: 1
  issue: 1
  year: 2019
  ident: 3522_CR42
  publication-title: JAMA Pediatr
  doi: 10.1001/jamapediatrics.2019.3875
  contributor:
    fullname: LJH Rasmussen
– volume: 206
  start-page: 347
  year: 2019
  ident: 3522_CR55
  publication-title: Schizophr Res
  doi: 10.1016/j.schres.2018.10.020
  contributor:
    fullname: M Brink
– volume: 29
  start-page: 240
  year: 2015
  ident: 3522_CR41
  publication-title: Med J Islam Repub Iran
  contributor:
    fullname: S Niroumand
– volume: 15
  start-page: 213
  issue: 1
  year: 2021
  ident: 3522_CR46
  publication-title: Early Interv Psychiatry
  doi: 10.1111/eip.12946
  contributor:
    fullname: J Ventura
– volume: 10
  start-page: e0140052
  issue: 10
  year: 2015
  ident: 3522_CR24
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0140052
  contributor:
    fullname: F Ventorp
– volume: 228
  start-page: 190
  year: 2021
  ident: 3522_CR25
  publication-title: Schizophr Res
  doi: 10.1016/j.schres.2020.11.051
  contributor:
    fullname: TT Bigseth
– volume: 68
  start-page: 349
  issue: 2–3
  year: 2004
  ident: 3522_CR36
  publication-title: Schizophr Res
  doi: 10.1016/S0920-9964(02)00490-5
  contributor:
    fullname: S Sarro
– volume: 12
  start-page: 117727191770419
  year: 2017
  ident: 3522_CR22
  publication-title: Biomark Insights
  doi: 10.1177/1177271917704193
  contributor:
    fullname: A Gustafsson
– volume: 11
  start-page: e0156624
  issue: 5
  year: 2016
  ident: 3522_CR52
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0156624
  contributor:
    fullname: JM Ramsey
– volume: 40
  start-page: 1526
  issue: 6
  year: 2014
  ident: 3522_CR3
  publication-title: Schizophr Bull
  doi: 10.1093/schbul/sbt200
  contributor:
    fullname: PR Nielsen
– volume: 29
  start-page: 931
  issue: 9
  year: 2019
  ident: 3522_CR54
  publication-title: Nutr Metab Cardiovasc Dis
  doi: 10.1016/j.numecd.2019.05.066
  contributor:
    fullname: M Cabral
– volume: 80
  start-page: 209
  issue: 2
  year: 2008
  ident: 3522_CR16
  publication-title: J Med Virol
  doi: 10.1002/jmv.21114
  contributor:
    fullname: O Andersen
– volume: 49
  start-page: 624
  issue: 8
  year: 1992
  ident: 3522_CR32
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.1992.01820080032005
  contributor:
    fullname: RL Spitzer
– volume: 22
  start-page: 39
  issue: S22
  year: 1993
  ident: 3522_CR34
  publication-title: Br J Psychiatry Suppl
  doi: 10.1192/S0007125000292581
  contributor:
    fullname: D Addington
– volume: 5
  issue: 7
  year: 2015
  ident: 3522_CR21
  publication-title: Transl Psychiatry
  doi: 10.1038/tp.2015.88
  contributor:
    fullname: M Bot
– volume: 273
  start-page: 524
  year: 2020
  ident: 3522_CR48
  publication-title: J Affect Disord
  doi: 10.1016/j.jad.2020.04.056
  contributor:
    fullname: W Li
– volume: 45
  start-page: 77
  year: 2014
  ident: 3522_CR9
  publication-title: Psychoneuroendocrinology
  doi: 10.1016/j.psyneuen.2014.03.019
  contributor:
    fullname: J Dahl
SSID ssj0017851
Score 2.3648655
Snippet There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and the association...
Abstract Background There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and...
Background There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and the...
BACKGROUNDThere is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and the...
Background - There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and the...
Abstract Background There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and...
SourceID doaj
pubmedcentral
cristin
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 527
SubjectTerms Basale medisinske, odontologiske og veterinærmedisinske fag: 710
Basic medical, dental and veterinary science disciplines: 710
Biomarkers
Blood levels
Body mass index
C-reactive protein
C-Reactive Protein - analysis
Complications and side effects
CRP
Demographic aspects
Depression
Depression - complications
Depression, Mental
Development and progression
Female
Females
Gender differences
Genetic aspects
Health aspects
Humans
Immune response
Inflammation
Lipids
Male
Medical disciplines: 700
Medisinske Fag: 700
Mental depression
Mental disorders
Psychiatry
Receptors, Urokinase Plasminogen Activator
Risk factors
Schizophrenia
Schizophrenia - complications
Sex
suPAR
Tissue plasminogen activator
Tobacco smoking
U-Plasminogen activator
Urokinase
VDP
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4t0tBRkJiQOKmvgdbgVRVUjlRKXeLL8CK3aT1Wa30L_TX9qZPJaNOHDhFq2dhz3feL5Zj2cIeas9D0GoKmMq6kzo5LOycjFLXDovUhGqbsf04qs6vxRfruTVXqkvjAnr0wP3E3eCGdrKIsiqCp3xK6Nmwhsng1Mm8p4a5eXoTA37B1hyfjwiY9RJC6swIALDETD_J8uQ7oZOi-qJQery9v-9Ou-Zp2no5J4tOntEHg4kkp72H_-Y3Ev1E3L_Ytgmf0pud5F1dNH8ot_XLiYKUALp9ycVqb-hCDq_SHS7bn7OazBmdAVMejmvG8AUxfMO1-iQU1gS0wovFhhf1MJzaLsfqfeBOtqm39lYTndD3R-RU_yfl47htteJtjdLeNiyfUYuzz5_-3SeDcUYsiCN3mSVqErjipRXuYg8iuSkKVQO1iwll3IXQExJiBL5lWA-COaiKV2FG6FGyYo_Jwd1U6dDQqNPWDGLga8ShValFzp3zHFZ-KCC5jNyOMjG1qAHmFaZa8tYaaDp_Sgsu-rTcdjOjTHK9kK2IGTbCdmqGfmI8tz1xFTa3Q8AMDsAzP4LYDPyDtFgUeFB5MEN5xZgLJg6y54qmAcgnTm87njSExQ1TJtHPNlhoWgteJ8lw9RXckbe7JrxTgx-q1OzxT5GAY0EMjwjL3r47YbEYe6AhUGLngBzMuZpSz3_0aURNxLu5ezof0zSS_KAoXaBUWfqmBxs1tv0Ctjaxr_uFPMOYwc_kA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: AUTh Library subscriptions: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF_0CuKL-N3UKisIPkhobrPZbHyRVlqK0CJioW_LfqUe3iXn5a61_45_qTPJJr0g-BZuN8lt5us3O7MzhLzLTWotF2XMhMtjnnsTF6V2sU8zbbif2rKNmJ6di9ML_uUyuwwbbk1Iq-x1YquoXW1xj_wAYHrBsEZQ9mn5K8auURhdDS007pMdBp5CMiE7R8fnX78NcQRsPd8flZHioAFtDJyBaQlYB5TFCHttK03VyDC19fv_1dJbZmqcQrllk04ek0cBTNLDjvpPyD1fPSUPzkK4_Bn5M2TY0Xl9Q69W2nkKLAVc0J1YpOaWIvOZuaebVf1zVoFRo0tA1ItZVQNvUTz3cI2OOQXV6Jd4Mcc8owaeQ5vtjL2PVNPG_477trprqu9IT3G_l_Zpt9eeNrcLeNiieU4uTo6_fz6NQ1OG2GYyX8clLwuppz4pE-5Sx73O5FQkYNW81z7RFhxOz3mBOIszYznTTha6xICoFFmZviCTqq78LqHOeOycxcBncTwXheF5oplOs6mxwuZpRHYDbVQF8oDlldNcMVZIGPrQE0stu7IcqnVnpFAdkRUQWbVEViIiR0jPYSaW1G5_qFdXKkiowlKAxdRmZWlblFW4nHEjdWa1kC7VEXmP3KBQ8IHkVofzC7AWLKGlDgV8BwCfCbxufzQTBNaOh3t-UkFhNOqOvSPydhjGOzEJrvL1BudIAXASQHFEXnbsNywphW8HaAxG8hFjjtY8HqlmP9py4jKDe1O29_-_9Yo8ZCg3YLaZ2CeT9WrjXwMeW5s3Qej-Ai9iOIo
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access(OpenAccess)
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbGkKa9IO4LG8hISDygQOI4joOE0EBME9J4otLeLNuxt4o2KUm7rX-HX8o5uXSN2BNvVW2ncr7v-JxTnwshbzKTWMuFD5kospBnzoS510XoklQb7mLr2xvTsx_idMK_n6fnO2Rod9S_wOZO1w77SU3q2fub3-vPIPCfWoGX4kMDZyzgjcEGWN2TheIeuc84eOoYysdvbxWwEf2QOHPnun2yl_AM1RpmN9lWzMqRxmoL-_97fG_pr3Fs5ZayOnlIHvRWJj3uaPGI7LjyMdk76-_Rn5A_m9A7Oquu6UWtC0dh90CPLpWRmjVFVpqZo6u6-jUtQdvRBZja82lZAekoJkRcocdO4cx0C_wwwwCkBp5Dm-1Qvo9U08bdhEO_3SXVt5yg-EcwHeJxrxxt1nN42Lx5SiYn335-PQ37bg2hTWW2DD33udSxi3zEi6TgTqcyFhGoO-e0i7QFT9RxnqMBxpmxnOlC5trjTakUqU-ekd2yKt0BoYVx2FKLgTNT8EzkBjDRTCdpbKywWRKQgx4bVYKgYN3lJFOM5RKG3g1gqUVXr0O1fo4UqsNbAd6qxVuJgHxBPDczsdZ2-0VVX6hedBXWCMxjm3pvW_MrLzLGjdSp1UIWiQ7IW2SDQo4C5Fb3iQ2wF6ytpY4FvAewSiP4uaPRTJBkOx4e-KQGQVDgnuYMa2OlAXm9GcaVGB1XumqFc6QAOxOs5YA87-i32dLA54BkI2KO9jweKaeXbZ1xmcLahL3475WHZJ-hdIGqZ-KI7C7rlXsJNtzSvGoF8y-tUEes
  priority: 102
  providerName: Scholars Portal
Title Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms
URI https://www.ncbi.nlm.nih.gov/pubmed/34702245
https://www.proquest.com/docview/2599252005
https://search.proquest.com/docview/2586993095
http://hdl.handle.net/10037/22983
https://pubmed.ncbi.nlm.nih.gov/PMC8547032
https://doaj.org/article/775491c5ffc741559d724b8a5ca68d3a
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swEBZtB2MvY7_rrQsaDPYw3CSyJMt7a0pLGaSUskLYi5BkuQ1L7BAn3frv7C_dnWJnMXvbiwmRZEe573R31ncnQj6mNnGOyyJmMk9jnnobZ4XJY58IY7kfuiLsmI4v5cUN_zoRkz0i2lyYQNp3dnpczubH5fQucCsXc9dveWL9q_GpEhyAyvr7ZB8A2obozdYBnjbfZsco2a9hAQYwIBMBS3-yGA8tSmA82C5MYXJBl8qOWQrV-_9do3eMVJdAuWORzp-Rp40rSU82P_k52fPlC_J43GyWvyS_t_w6Oqt-0tulyT0FQAEGNvmK1D5QhJ6debpeVj-mJZg0ugB_ej4tK0AWxayHewzLKSyMfoEfZsgyquE-tN7l632hhtb-V9weqrui5q_gKb7tpS3p9t7T-mEON5vXr8jN-dm304u4OZIhdkKlq7jgRabM0A-KAc-TnHsj1FAOwKZ5b_zAOAg3PecZelmcWceZyVVmCtwOVVIUyWtyUFalPyQ0tx7PzWIQseQ8lZkFmRhmEjG0Tro0ichhIxtdgjZgceUk1YxlCpo-t8LSi01RDh2CGSX1Rt4a5K2DvLWMyAjlue2JBbXDF9XyVjew0lgIMBs6URQu-FhZnjJulRHOSJUnJiKfEA0a1R5E7kyTvQBzwQJa-kTC_wCu5wAed9TpCerqus0tnnSzXNQaYtCMYQEsEZEP22YciRS40ldr7KMkOJPgEkfkzQZ-2ym1eI5I2gFmZ87dFtCtUEy80aW3_z3yHXnCULvAnjN5RA5Wy7V_D47ayvZAPSdpjzwanV1eXffC6w64jrmC6_Xoey8o7h-pjEV9
link.rule.ids 230,315,730,783,787,867,888,2109,12068,21400,24330,27936,27937,31731,31732,33756,33757,43322,43817,53804,53806
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgSMAL4nuFAUZC4gFFSx3HdnhBAzEVWPe0SX2z_JVR0SalaQf7d_hLuXOTrhESb1HPSerc1-_s8x0hb6TNnOOiTJjwMuEy2KQojU9ClhvLw9CVccd0fCpG5_zrJJ-0C25Nm1bZ2cRoqH3tcI38EGB6wbBGUP5h8TPBrlG4u9q20LhJbmEdLuxgICfbgCs2nu8Oyihx2IAtBrnApASsAsoSBL0u6lLVc0uxev-_NnrHSfUTKHc80vF9cq-FkvRow_sH5EaoHpLb43az_BH5s82vo7P6F71YGh8oCBTIwOa8IrVXFEXPzgJdL-sf0wpcGl0Anp5Pqxoki-Kph0sMyykYxrDAixlmGTXwHNrs5uu9p4Y24XfSNdVdUXPNeIqrvbRLur0MtLmaw8PmzWNyfvz57NMoaVsyJC5XcpWUvCyUGYa0TLnPPA8mV0ORgk8LwYTUOAg3A-cFoizOrOPMeFWYErdDlcjL7AnZq-oq7BPqbcC-WQwiFs-lKCyXqWEmy4fWCSezAdlveaMr0AYsrpxJzVihgPSuY5ZebIpy6BjMKKE3TNbAZB2ZrMWAfER-bkdiQe34Q7280K1-aiwEWAxdXpYuYqzCS8atMrkzQvnMDMhblAaNag8sd6Y9vQBzwQJa-kjAdwDomcLrDnojQV1dn9zJk27NRaOvhXtAXm_JeCemwFWhXuMYJQBMAiQekKcb8dtOKYNvB1gMKLInmL059ynV9HssJq5yuDdjz_7_t16RO6Oz8Yk--XL67Tm5y1CHwIEzcUD2Vst1eAHIbGVfRvX7C9k4OhU
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdgSBMviO9lG2AkJB5Q1tRxHIe3MajGR6c9MGlvlr-yVbRJ1bSD_Tv8pdy5SWnEG29V7bh173e-u_p3d4S8yU1qLRdlzITLY557ExeldrFPM224H9oy3JiOz8TpBf9ymV1utfoKpH1rJkfVdHZUTa4Dt3I-s4OOJzY4H5_IjANQ2WDuysFdcg90NhFdoN5eIGDP-S5HRopBA8cwQAL5CFgAlMXYuiiFVcCCYSKTDRpV9YxTqOH_70m9Zar6NMotuzR6SB60DiU9Xn_xR-SOrx6T3XF7Zf6E_N6w7Oi0_kmvFtp5CrACJKyzFqm5pQhAM_V0tah_TCowbHQOXvVsUtWAL4q5DzcYnFM4Hv0cX0yRa9TAOrTZZu29p5o2_lfctdZdUv1X_BT_86Ud9fbG0-Z2BovNmqfkYvTp-8lp3DZmiG0m82Vc8rKQeuiTMuEuddzrTA5FApbNe-0TbSHo9JwX6GtxZixn2slCl3gpKkVWps_ITlVXfo9QZzx2z2IQtziei8KATDTTaTY0Vtg8jcheKxtVgU5gieU0V4wVEobedcJS83VpDhVCGinUWt4K5K2CvJWIyAeU52YmltUOb9SLK9WCS2E5wGJos7K0wdMqXM64kTqzWkiX6oi8RTQoVH4QudVtDgPsBctoqWMBvwM4oAl83GFvJiit7Q93eFLtodEoiEQLhmWwsoi83gzjk0iEq3y9wjlSgEsJjnFEnq_ht9lSh-eI5D1g9vbcHwENCyXFW43a_-8nX5Hd848j9e3z2dcDcp-hooGBZ-KQ7CwXK_8CPLeleRl09A_IH0SH
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Exploring+low+grade+inflammation+by+soluble+urokinase+plasminogen+activator+receptor+levels+in+schizophrenia%3A+a+sex-dependent+association+with+depressive+symptoms&rft.jtitle=BMC+psychiatry&rft.au=Bigseth%2C+Therese+Torgersen&rft.au=Engh%2C+John+Abel&rft.au=Egeland%2C+Jens&rft.au=Andersen%2C+Eivind&rft.date=2021-10-26&rft.pub=BioMed+Central&rft.eissn=1471-244X&rft.volume=21&rft_id=info:doi/10.1186%2Fs12888-021-03522-6&rft_id=info%3Apmid%2F34702245&rft.externalDBID=PMC8547032
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-244X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-244X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-244X&client=summon